共 170 条
[1]
Husted S(2009)Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist Cardiovasc Ther 27 259-274
[2]
Giezen JJ(2006)Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 1038-1047
[3]
Husted S(2007)Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 50 1852-1856
[4]
Emanuelsson H(2010)Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers Br J Clin Pharmacol 70 65-77
[5]
Heptinstall S(2010)Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects Eur J Clin Pharmacol 66 487-496
[6]
Sandset PM(1994)The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A J Thromb Haemost 72 313-317
[7]
Wickens M(2009)Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation J Thromb Haemost 7 556-565
[8]
Peters G(2010)Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite Drug Metab Dispos 38 898-904
[9]
Storey RF(2010)Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects Drug Metab Dispos 38 1514-1521
[10]
Husted S(2008)Optimizing platelet inhibition Eur Heart J 10 D23-D29